XNASATXS
Market cap439mUSD
Jan 15, Last price
7.79USD
1D
5.70%
1Q
-33.76%
Jan 2017
-78.42%
IPO
-42.17%
Name
Astria Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
104.49%
Rev. gr., 5y
%
Revenues
0k
Net income
-73m
L+45.30%
CFO
-68m
L+57.23%
Earnings
Mar 03, 2025
Profile
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 83,030 | 53,503 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (83,030) | (53,503) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,669) | ||||||||
Tax Rate | |||||||||
NOPAT | (83,030) | (51,834) | |||||||
Net income | (72,891) 45.30% | (50,165) 66.26% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 87,978 | 144,637 | |||||||
BB yield | -38.03% | -66.44% | |||||||
| Debt | |||||||||
Debt current | 658 | 582 | |||||||
Long-term debt | 329 | 1,296 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 8,478 | ||||||||
Net debt | (245,543) | (224,559) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (68,445) | (43,533) | |||||||
CAPEX | (25) | (91) | |||||||
Cash from investing activities | 135,052 | (167,129) | |||||||
Cash from financing activities | 88,398 | 144,721 | |||||||
FCF | (81,192) | (53,641) | |||||||
| Balance | |||||||||
Cash | 246,530 | 226,437 | |||||||
Long term investments | |||||||||
Excess cash | 246,530 | 226,437 | |||||||
Stockholders' equity | (485,169) | (411,296) | |||||||
Invested Capital | 728,943 | 641,929 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 30,123 | 14,621 | |||||||
Price | 7.68 -48.42% | 14.89 176.25% | |||||||
Market cap | 231,347 6.27% | 217,701 352.54% | |||||||
EV | 81,128 | 89,540 | |||||||
EBITDA | (83,030) | (53,503) | |||||||
EV/EBITDA | |||||||||
Interest | 1,669 | ||||||||
Interest/NOPBT | |||||||||